Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Journal of the National Cancer Institute - 16 Feb 2011

Drew Yvette, Mulligan Evan A, Vong Wan-Tse, Thomas Huw D, Kahn Samra, Kyle Suzanne, Mukhopadhyay Asima, Los Gerrit, Hostomsky Zdenek, Plummer Elizabeth R, Edmondson Richard J, Curtin Nicola J

Abstract excerpt

BACKGROUND: Mutations in BRCA1 and BRCA2 (BRCA1/2), components of the homologous recombination DNA repair (HRR) pathway, are associated with hereditary breast and ovarian cancers. Poly(ADP-ribose) polymerase (PARP) inhibitors are selectively cytotoxic to animal cells with defective HRR, but results in human cancer cells have been contradictory. We undertook, to our knowledge, the first comprehensive in vitro and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Cricetulus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Indoles

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 21183737
DOI: 10.1093/jnci/djq509

Genes

BRCA1
BRCA2
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.PMID 21183737Read ↗

The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer TreatmentSemantic proximity Read ↗

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitorsSemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

Current status of poly(ADP-ribose) polymerase inhibitors and future directionsSemantic proximity Read ↗

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.Semantic proximity Read ↗

Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.Semantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.Semantic proximity Read ↗

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors as cancer therapySemantic proximity Read ↗

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer TherapySemantic proximity Read ↗

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human CellsSemantic proximity Read ↗

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.